Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors

Scottish Medicines Consortium
Record ID 32018000972
Authors' objectives: To assess clinical and cost effectiveness.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Scotland, United Kingdom
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Antineoplastic Agents
  • Lung Neoplasms
  • Protein Kinase Inhibitors
Organisation Name: Scottish Medicines Consortium (SMC)
Contact Address: Delta House | 50 West Nile Street
Contact Name: Susan Downie
Contact Email: susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.